SUBSCRIBE ARCHIVE PRINT June 10, 2022 Eyenovia Announces Planned Transition of CEO Advertisement Eyenovia has announced that “co-founder, chief medical officer, and chief executive officer (CEO) Dr. Sean Ianchulev will step down as CEO.” According to a press release, he will “transition to the role of non-executive chairman of the board” over a timeline still to be determined. The company says it has “retained an executive search firm to assist in identifying the next CEO,” and says “Dr. Ianchulev will continue as a consulting medical director to support ongoing clinical development activities and trials.” Dr. Ianchulev was quoted in the press release saying, “With the upcoming milestones of re-filing the MydCombi NDA and completing our second Phase III study for our Microline presbyopia program in clear sight, consistent with our previously disclosed timelines, I feel that now is the appropriate time to move into the non-executive chairman role and to focus my energy on ophthalmic innovation for the next wave of clinical therapies and technologies.” More information can be found at https://www.globenewswire.com/news-release/2022/06/07/2457617/0/en/Eyenovia-Announces-Planned-Chief-Executive-Officer-Transition.html. Lento Bio Developing Anti-Glycation Drugs for Presbyopia Lento Bio has “announced its launch [as a] company initially focused on developing pharmaceutical eyedrops to treat presbyopia…Lento Bio will be supported and incubated by Ichor Life Sciences, a preclinical contract research organization.” The company says the small-molecule drugs it is developing “will target underlying molecular damage accumulation with the goal of reversing the process of tissue stiffening in the ocular lens.” More information can be found at https://www.digitaljournal.com/pr/lento-bio-an-ichor-life-sciences-portfolio-company-launches-with-aims-to-develop-anti-glycation-drugs-for-presbyopia-and-diseases-of-aging. Nyxol Trial Results Announced Ocuphire Pharma has “announced positive topline results from the LYNX-1 Phase 3 pivotal clinical trial [of] its product candidate Nyxol for night (or dim light) vision disturbances (NVD).” The company says “over 650 subjects have been exposed to Nyxol, across 12 U.S. clinical trials.” In a press release, founder and CEO Mina Sooch, MBA, said the company “will focus on the pivotal trials for presbyopia and on the NDA submission and pre-commercial activities for Nyxol in reversal of mydriasis (RM).” She added, “Importantly, the LYNX-1 trial results provide additional support for the safety and vision improvement benefits of Nyxol in RM and presbyopia in dim light conditions.” More information can be found at https://www.ocuphire.com/news-media/press-releases/detail/374/ocuphire-announces-positive-topline-results-from-lynx-1. Ocuphire CEO Participates in Virtual Ophthalmology Panel Mina Sooch, MBA, founder and CEO of Ocuphire Pharma, recently participated “in a virtual ophthalmology panel discussion hosted by Kristen Kluska, managing director, Biotechnology Equity Research at Cantor Fitzgerald.” The topics included discussion on Ocuphire’s Nyxol eye drops, which Ocuphire says “reported positive late-stage clinical data in all 6 readouts from Phase 3 trials in reversal of mydriasis (RM), pediatric RM, and night vision disturbances, as well as a Phase 2 trial in presbyopia.” More information can be found at https://www.ocuphire.com/news-media/press-releases/detail/375/ocuphire-to-present-new-interim-masked-safety-data-for-oral.